Strategic and Tactical Competitive Insights
We deliver crucial insights that empower clients to make winning strategic decisions.
Our consulting uncovers threats/opportunities, empowering clients to make strategic decisions that yield winning outcomes.
We deliver evidence-based recommendations, informed by expert interviews, to help clients address issues across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
We provide decision support across the product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
With timely insights across therapy areas, we equip clients to accelerate competitive advantage.
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
October 28, 2025
Obesity Today — October 28, 2025
October 28, 2025
Lucid Diligence Brief: Guardant Health and Zephyr AI partnership
October 28, 2025
Obesity Video Recap — October 28, 2025
October 27, 2025
Hematology Today — October 27, 2025
October 27, 2025
Oncology Video Recap — October 27, 2025
October 27, 2025
Oncology Today — October 27, 2025
October 27, 2025
AI in Healthcare and Digital Health Today—October 27, 2025
October 27, 2025
Lucid Diligence Brief: Novartis to acquire Avidity Biosciences
October 26, 2025
Lucid Diligence Brief: ENA Respiratory Series B for Intranasal INNA-051
October 25, 2025
Lucid Diligence Brief: Lilly to acquire Adverum Biotechnologies
October 24, 2025
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A
October 24, 2025